Search Results

Philogen S.p.A announced that it has entered into a Service and Supply Agreement with IBSA to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena.

Philogen S.p.A. announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD.

Sun Pharmaceutical Industries Limited and Philogen S.p.A announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ in the territories of Europe, Australia and New Zealand.

Philogen S.p.A. announces the publication of the latest results of Fibromun in combination with lomustine for the treatment of glioblastoma in Science Translational Medicine describing how the combination treatment cured orthotopic glioma-bearing mice and mediated durable objective responses and major tumor shrinkage in patients with recurrent glioblastoma.

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding recent corporate developments.

Philogen S.p.A. today announces that it will present at the UBS Global Healthcare Conference on May 25, 2022 at the Lotte New York Palace.

Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, announces the publication of a study in the peer-reviewed journal “Chem” describing the design, development and the in vivo characterization of novel OncoFAP ligands.

Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A.

Philogen S.p.A. (BIT:PHIL) and Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299).

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, is pleased to announce the enrolment of 214 patients, in line with the protocol of its Phase III European trial of Nidlegy™ in locally advanced melanoma.